Published in J Cardiovasc Pharmacol on April 22, 1982
Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol (2004) 0.86
Release of a neutrophil-derived vasoconstrictor agent which augments platelet-induced contractions of blood vessels in vitro. Br J Pharmacol (1990) 0.81
Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review. Agents Actions (1984) 0.77
Inflammatory mediators released by complement-derived peptides. Agents Actions (1983) 0.75
Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine. Agents Actions (1984) 0.75
Influence of ketanserin on glucose and lipid metabolism in diabetic patients with hypertension. Drugs (1988) 0.75
MSTRAT: an algorithm for building germ plasm core collections by maximizing allelic or phenotypic richness. J Hered (2001) 1.93
Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies. Infect Immun (1988) 1.92
Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein. J Biol Chem (1988) 1.88
Maternal food restriction in the second half of pregnancy affects vascular function but not blood pressure of rat female offspring. Br J Nutr (1999) 1.72
Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol (2001) 1.70
High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology (1994) 1.60
Neutral genetic markers and conservation genetics: simulated germplasm collections. Genetics (1996) 1.44
Estimation of long-term effective population sizes through the history of durum wheat using microsatellite data. Genetics (2004) 1.16
5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet (1981) 1.15
Inferring recent outcrossing rates using multilocus individual heterozygosity: application to evolving wheat populations. Genetics (2000) 1.15
Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs. Arch Int Pharmacodyn Ther (1982) 1.13
Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg (1987) 1.11
Streptozotocin diabetes in the pregnant rat induces cardiovascular dysfunction in adult offspring. Diabetologia (1999) 1.09
Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J Biol Chem (1985) 1.08
Deleterious mutation accumulation and the regeneration of genetic resources. Proc Natl Acad Sci U S A (1998) 1.05
Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions (1982) 1.04
SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery. Ann Thorac Surg (2000) 1.01
Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol (1986) 0.99
Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol (2001) 0.99
Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. J Am Coll Cardiol (1990) 0.96
The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation. A biochemical and functional analysis using the novel diacylglycerol kinase inhibitor, R 59 949. J Biol Chem (1989) 0.95
Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thromb Res (1982) 0.95
The rheological effects of cinnarizine and flunarizine in normal and pathologic conditions. Angiology (1979) 0.94
Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol (2000) 0.94
Factors affecting polymorphism at microsatellite loci in bread wheat [ Triticum aestivum (L.) Thell]: effects of mutation processes and physical distance from the centromere. Theor Appl Genet (2003) 0.91
Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol (1984) 0.91
Effects of anti-inflammatory, anticoagulant and vasoactive compounds on tail bleeding time, whole blood coagulation time and platelet retention by glass beads in rats. Thromb Res (1976) 0.91
Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg (1984) 0.90
Ischemia/reperfusion-induced arrhythmias in anaesthetized rats: a role of Na+ and Ca2+ influx. Eur J Pharmacol (1999) 0.90
Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology (1984) 0.88
New trends in thromboxane and prostacyclin modulators. Curr Med Chem (2000) 0.88
Increased TGFbeta1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest (2002) 0.87
Oxatomide protects Trichinella spiralis infected mice from lethal anaphylaxis. Agents Actions (1978) 0.87
Modulation of airway hyperresponsiveness by thiols in a murine in vivo model of allergic asthma. Inflamm Res (2003) 0.86
Synthetic inhibitors of human tissue kallikrein. Immunopharmacology (1996) 0.86
Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat. Agents Actions (1983) 0.86
Ticlopidine and coronary surgery. Agents Actions Suppl (1984) 0.85
Direct evidence for the contractile capacity of endothelial cells. Thromb Res (1981) 0.85
Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc Res (2001) 0.84
Genetic relationships between diploid and allotetraploid cherry species (Prunus avium, Prunus x gondouinii and Prunus cerasus). Heredity (Edinb) (2004) 0.84
Blood hyperviscosity in spontaneously hypertensive rats. Thromb Res (1980) 0.84
Are there sex-specific differences in ventricular repolarization or in drug-induced early afterdepolarizations in isolated rabbit purkinje fibers? J Cardiovasc Pharmacol (2000) 0.84
Calcium sensors as new therapeutic targets for airway hyperresponsiveness and asthma. FASEB J (2001) 0.83
Method for the measurement of 14 C-5 HT uptake and release by platelets. Adv Exp Med Biol (1972) 0.83
The synergistic effect of 5-hydroxytryptamine and epinephrine on the human platelet is related to the activation of phospholipase C. Eur J Pharmacol (1993) 0.83
Virus-induced airway hyperresponsiveness in the guinea-pig: possible involvement of histamine and inflammatory cells. Br J Pharmacol (1993) 0.83
Effect of flunarizine on the human red cell shape changes and calcium deposition induced by A 23187. Thromb Res (1982) 0.82
Thromboxane A2-induced vascular endothelial cell damage and respiratory smooth muscle cell contraction: inhibition by flunarizine, a Ca2+-overload blocker. Arch Int Pharmacodyn Ther (1985) 0.82
Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker. Biochem Pharmacol (1983) 0.82
Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis. J Cardiovasc Pharmacol (1993) 0.82
Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung. J Pharmacol Exp Ther (1992) 0.81
R 56 865, a Na+/Ca(2+)-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivo. J Cardiovasc Pharmacol (1993) 0.81
Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res (1979) 0.81
The effect of flunarizine treatment on human red blood cells. Angiology (1979) 0.81
The involvement of 5-HT2-receptor sites in the activation of cat platelets. Thromb Res (1984) 0.80
Selective vasoconstriction by alniditan in the carotid vascular bed of anaesthetized dogs. Eur J Pharmacol (1996) 0.80
The synergistic effect of serotonin and epinephrine on the human platelet at the level of signal transduction. FEBS Lett (1987) 0.80
Demonstration of S2-receptor binding sites on cat blood platelets using [3H]ketanserin. Eur J Pharmacol (1983) 0.80
Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations. Blood Coagul Fibrinolysis (1991) 0.80
Protection by flunarizine against endothelial cell injury in vivo. Angiology (1981) 0.80
Nocodazole, a new synthetic antimitotic agent, enhances the production of plasminogen activator by cells in culture. Thromb Res (1977) 0.78
Heparin-induced thrombocytopenia: a case report. Angiology (1990) 0.78
Assay of platelet ATP and ADP by the luciferase method: some theoretical and practical aspects. Adv Exp Med Biol (1972) 0.78
Platelet-mediated vascular permeability in the rat: a predominant role for 5-hydroxytryptamine. Thromb Res (1985) 0.78
Dissociation of clot retraction from platelet granule fusion and degranulation: an ultrastructural study of Reptilase-human platelet-rich plasma clots. Br J Haematol (1975) 0.78
Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. In vitro experiments. Arch Int Pharmacodyn Ther (1975) 0.78
Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot Essent Fatty Acids (2003) 0.78
The use of perfluorodecalin in diabetic vitrectomy. Fortschr Ophthalmol (1991) 0.78
Reduction by flunarizine of the increase of blood viscosity after ischemic forearm occlusion. Arch Int Pharmacodyn Ther (1977) 0.77
Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review. Agents Actions (1984) 0.77
Antiarrhythmic effects of nebivolol in experimental models in vivo. J Cardiovasc Pharmacol (1994) 0.77
Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro. Agents Actions (1986) 0.77
Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. Eur J Pharmacol (1993) 0.77
Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine. Zentralbl Veterinarmed A (1996) 0.77
Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH. Thromb Res (1985) 0.77
Does the antiarrhythmic effect of ischemic preconditioning in rats involve the L-arginine nitric oxide pathway? J Cardiovasc Pharmacol (1995) 0.77
Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells. Agents Actions (1981) 0.77
Differential effects of nebivolol on adrenoceptors in the heart and in resistance arterioles in the rat. Quantitative intravital microscopic analysis. Eur J Pharmacol (1990) 0.77
The effect of the intracellular calcium chelator Quin-2 on the platelet phosphoinositide metabolism, protein phosphorylation and morphology. Thromb Haemost (1987) 0.76
Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev (2001) 0.76
Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids (2003) 0.76
The protection by ischemic preconditioning against myocardial ischemia- and reperfusion-induced arrhythmias is not mediated by ATP-sensitive potassium channels in rats. Coron Artery Dis (1993) 0.76
Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist. Arch Int Pharmacodyn Ther (1984) 0.76
Blood platelets in human essential hypertension. Agents Actions (1986) 0.76
Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins Leukot Essent Fatty Acids (2001) 0.76
Reduction in QT dispersion and ventricular arrhythmias by ischaemic preconditioning in anaesthetized, normotensive and spontaneously hypertensive rats. Fundam Clin Pharmacol (1999) 0.75
S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect. Thromb Haemost (1986) 0.75
Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine. Agents Actions (1984) 0.75
Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids (2000) 0.75
[Hemostasis deficiencies in stomatological practice]. Rev Belge Med Dent (1981) 0.75
[Attempted induction of an experimental thrombosis in rabbits by means of purified collagen]. C R Seances Soc Biol Fil (1969) 0.75
[Platelet function and tests for their ascertainment]. Acta Clin Belg (1975) 0.75
Proceedings: Response of normal and pathological platelets to heparin added in vitrio and in vivo. Thromb Diath Haemorrh (1975) 0.75
Platelet factor 3 availability and kinetics of platelet aggregation. Acta Med Scand Suppl (1971) 0.75
[Antithrombotic therapy]. Rev Med Liege (1980) 0.75
[Platelet release reaction and atherogenesis: facts and hypotheses (author's transl)]. Rev Med Brux (1981) 0.75
[Platelet adhesion and aggregation]. Acta Clin Belg (1977) 0.75
Prolonged course of hepatic granulomatous disease due to Bartonella henselae infection. Acta Gastroenterol Belg (2017) 0.75
New platelet diseases. Acta Med Scand Suppl (1971) 0.75